STOCK TITAN

Standard BioTools Inc. - $LAB STOCK NEWS

Welcome to our dedicated page for Standard BioTools news (Ticker: $LAB), a resource for investors and traders seeking the latest updates and insights on Standard BioTools stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Standard BioTools's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Standard BioTools's position in the market.

Rhea-AI Summary

Standard BioTools announced participation in several investor conferences in June 2024. The schedule includes:

- Jefferies Global Healthcare Conference on June 5th & 6th, where CEO Michael Egholm will join a fireside chat on June 5th at 2:30 p.m. ET.

- Scotiabank Healthcare 1x1 Day on June 20th, featuring 1x1 investor meetings in Toronto, Canada.

- TD Cowen’s 3rd Annual Tool/Dx Revolution Conference from June 24th to 26th, with CEO Michael Egholm participating in a panel discussion on M&A consolidation on June 25th at 11:50 a.m. PT.

Presentations will be webcast live on the company's Investor Relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.77%
Tags
conferences
-
Rhea-AI Summary

Standard BioTools announced the grant of 207,832 restricted stock units (RSUs) under its 2022 Inducement Equity Incentive Plan, effective May 20, 2024. This grant serves as an inducement for a new employee and complies with Nasdaq Listing Rule 5635(c)(4).

The RSUs will vest initially on May 20, 2025, with 1/4th of the shares vesting on this date. Following this, 1/16th of the shares will vest every three months, contingent upon the employee's continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.39%
Tags
none
-
Rhea-AI Summary

Standard BioTools Inc. announced its first quarter 2024 financial results, showcasing strong revenue growth, operating expense synergies, and a path to cash flow positivity by 2026. The company reported pro forma combined revenue of $46.2 million, gross margin of 49.2%, and operating expense reductions. With a cash balance of $464 million, Standard BioTools is on track to achieve its long-term growth initiatives.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.59%
Tags
Rhea-AI Summary
Standard BioTools Inc. announced an operational restructuring plan to drive long-term profitable growth, expecting $45-$50 million in annual operating expense savings by fiscal 2025. The plan includes a reduction of approximately 10% of its total workforce, streamlining operational expenditures, and closing the R&D facility in San Diego.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
none
-
Rhea-AI Summary
Standard BioTools Inc. announces a conference call and webcast for the first quarter 2024 financial results on May 8, 2024. The Company will report the financial results after the market closes. The management will discuss the results and operational progress during the conference call and webcast. Interested individuals can listen to the call by dialing specific numbers or accessing the live audio webcast on the Company's website. The webcast will be archived for future reference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.48%
Tags
-
Rhea-AI Summary
Standard BioTools Inc. (Nasdaq:LAB) introduces new automation solutions to enhance the Imaging Mass Cytometry workflow on the Hyperion XTi Imaging System, revolutionizing spatial biology in clinical and translational research. The advancements aim to increase sample throughput, provide rapid and detailed spatial analysis, and offer high-throughput tissue imaging capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
none
Rhea-AI Summary
Standard BioTools Inc. (LAB) partners with Bristol Myers Squibb to utilize the SomaScan Platform for clinical trials in multiple therapeutic areas. The platform offers a comprehensive analysis of proteomic biomarkers, aiding in drug response assessment and patient population identification.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.38%
Tags
none
-
Rhea-AI Summary
Standard BioTools Inc. (LAB) announces the exchange of Series B Preferred Stock for common stock with Viking Global Investors and Casdin Capital, aiming to streamline capital structure and attract new investors. The exchange resulted in the issuance of approximately 93 million shares of common stock at $2.75 per share, reducing dilution to less than 5%. The Company now has around 382.5 million shares outstanding.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.15%
Tags
none
-
Rhea-AI Summary
Standard BioTools Inc. achieved its FY2023 core financial objectives by reducing expenses and cash burn while increasing revenue and gross margins. The merger with SomaLogic strengthened the company's position in life sciences, resulting in combined pro forma revenue of $192 million and a balance sheet with $565 million in combined pro forma cash, cash equivalents, restricted cash, and short-term investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.06%
Tags
Rhea-AI Summary
Standard BioTools Inc. (LAB) and Next Gen Diagnostics have signed a long-term agreement to enhance the automation of pathogen whole genome sequencing. The NGD-100, a version of Standard BioTools' Biomark X9 System, will be customized for NGD to streamline sample preparation. This collaboration aims to reduce the cost of bacterial sequencing to under $10/sample, addressing the key barriers in pathogen WGS. Standard BioTools' microfluidics technology, known for its scalability and automation, combined with NGD's advanced bioinformatics, will offer integrated pathogen sequencing services with rapid turnaround times and cost-efficiency. NGD has validated the accuracy of sequence-based diagnostics for antibiotic resistance prediction and infection transmission detection. The partnership signifies a significant advancement in Standard BioTools' growth strategy, expanding its microfluidic platform's impact in life sciences.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.86%
Tags
partnership
Standard BioTools Inc.

Nasdaq:LAB

LAB Rankings

LAB Stock Data

939.60M
50.24M
0.69%
56.05%
2.67%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
SOUTH SAN FRANCISCO

About LAB

fluidigm (nasdaq:fldm) develops, manufactures and markets microfluidic systems for growth markets in the life sciences and in applied markets. fluidigm’s systems consist of instruments, software, integrated fluidic circuits (ifcs), high-performance assays for gene expression and genotyping, and primers for sample preparation for next-generation sequencing. fluidigm technology enables customers to perform thousands of sophisticated biochemical measurements in parallel on samples smaller than the content of a single cell, with nanoliter volumes of reagents, in half the area of a credit card. the company’s integrated customer solutions are designed to significantly simplify experimental workflows, increase throughput and reduce costs while delivering excellent data quality. based in south san francisco, fluidigm offers an exciting and collegial working environment with excellent compensation and benefits, including equity.